VACCINE SAFETY
These mid-caps have ‘strong buy’ & ‘buy’ recos and upside potential of up to 28%, according to analysts
Global markets on Wednesday celebrated the outcome of the US mid-term election as well as a sharp drop in oil prices. Oil prices, which at the end of last week were at about $118 to the barrel, are now under $95. The hope clearly is that Democrat control of both chambers of the US Congress will pressure the Trump administration to pursue a diplomatic end to the conflict with Iran in the Gulf.
- Go To Page 1
With most drug candidates failing in humans, India’s draft rules bet on the wrong science in animal lab testing
Recent draft rules in India threaten advancements in non-animal testing for drug development and safety. The new regulations may prioritize animal testing over innovative human-based methods, despite their proven reliability. Efforts to incorporate non-animal methodologies into national standards have gained support from various government initiatives. Significant funding has been allocated to promote alternative testing methods throughout the country.
His grandfather died of pancreatic cancer: This Hyderabad startup founder is using AI to develop a personalised cancer vaccines
Hyderabad-based biotech startup PopVax, founded by Soham Sankaran, is developing AI-powered personalised cancer vaccines using mRNA technology. Inspired partly by his family's experience with pancreatic cancer, he aims to help the immune system identify and attack cancer cells using treatments designed around individual patients' tumour genetics.
These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analysts
When a market is as jittery as it is right now, poor numbers are treated harshly. A new-age company in the business of buying and selling used cars reported numbers that fell short, and the street punished the stock severely. But it is not just the clear misses. Anything that is well-owned and presents disappointing numbers is seeing double-digit cuts.
Gajab Raat ending explained: Who is the mystery girl Arya? Manoj Bajpayee’s fight against corruption
Gajab Raat is a gripping crime thriller that stars Manoj Bajpayee as a morally compromised police officer in Delhi. His investigation into an injured journalist, Arya Sahni, unveils a sinister plot involving influential figures. With recorded evidence of a planned vaccine shortage for profit, Ajay Nirvit faces a dilemma: protect Arya from political threats while secretly pursuing truth. Read on to find out what happens in the end.
450 villagers in UP’s Gorakhpur get rabies shots after consuming charanamrit served during Durga Puja, following cow’s death after suspected dog bite
A vaccination drive was launched in two Gorakhpur villages after a cow died following unusual behaviour, raising fears of possible rabies exposure among people who had consumed a religious offering made using its milk. Health workers administered anti-rabies shots to around 450 residents as a precaution, though the animal's infection has not been confirmed.
Strong majority of voters believes Trump is failing at home and abroad: AP-NORC poll
Federal authorities are investigating suspicious mailings received by congressional and election offices across the country. With Election Day approaching, the mailings are deemed potentially hazardous by law enforcement. In time, US President Trump plans to host rallies in support of Republican candidates in Iowa. Candidates are also navigating fundraising challenges as the midterm elections draw near. The political landscape appears increasingly competitive with various races across states tight.
Flu shots, vaccines latest update: Donald Trump's Health Secretary Robert Kennedy Jr. launches new push on vaccine injuries. All you need to know
Robert Kennedy Jr. has said US children receive too many vaccines, falsely claiming repeatedly that kids get up to 90 doses before age 18, which has been echoed by President Donald Trump.
When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%
Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends on what it chose in the last five or six. So, one name can do wonderfully while the one sitting next to it does very little. Stock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. The simple average of the above-mentioned five component ratings is normally distributed to reach an average score.
Ashwagandha’s 24-week safety test brings reassuring findings: Report
A clinical trial involving 1,200 adults evaluated the safety of standardised ashwagandha root extract. Participants took either ashwagandha or a placebo for 24 weeks without adverse effects on liver or kidney function. The study monitored participants' immune responses following COVISHIELD vaccination. Results indicated that ashwagandha did not impact virus-neutralising activity compared to the placebo group. This trial adds to the evidence supporting the safety of Ayurveda interventions.
Load More
